Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Revenue of Pliant Therapeutics, Inc. (PLRX)
Revenue in 2023 (TTM): $1.58 M
According to Pliant Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $1.58 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Pliant Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.58 M | $-261,000 | $-158,228,000 | $-161,336,000 | $-161,336,000 |
| 2022 | $9.69 M | $6 M | $-118,849,000 | $-123,321,000 | $-121,498,000 |
| 2021 | $7.57 M | $4.37 M | $-95,728,000 | $-19,714,000 | $-17,907,000 |
| 2020 | $41.82 M | $41.82 M | $-40,335,000 | $-41,533,000 | $-39,745,000 |
| 2019 | $57.05 M | $57.05 M | $-118,000 | $-631,000 | $185 K |
| 2018 | $ | $-666,000 | $-30,249,000 | $-30,276,000 | $-30,276,000 |
| 2017 | $ | $ | $-18,057,000 | $-18,333,000 | $-20,622,000 |